BNET Industries

Discovery Laboratories Inc.

(DSCO) is in the Pharma Industry

Market Cap:$93.5M
Last Fiscal Year Sales:$4.6M
  • Public
  • US
Dow Jones Description

Discovery Laboratories, Inc. is a biotechnology company developing Surfactant Therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 Surfactant Technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol or lyophilized formulations. In addition, Discovery Labs' proprietary Capillary Aerosolization Technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies.

Interim Chief Executive Officer
W. Thomas Amick
Number of Employees 118
Contact Information

2600 Kelly Rd Ste 100

Warrington, Pennsylvania 18976-3622

www.Discoveryla...

(215) 488-9300

NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414

Recent Events

  • BUYINS.NET: Discovery Laboratories DSCO Daily Short Sale Trading Volume Through 11-17-09. Over 56 Million Shares...

    11/19/09 - Joint Venture / Alliance - View Story

  • BUYINS.NET: REGN, EGLE, VG, SSS, DSCO, SRDX Expected To Be Lower After Earnings Releases on...

    11/02/09 - Joint Venture / Alliance - View Story

  • ATVI, FLEX, BRCM, DSCO, ONNN, AMLN With Highest Daily Short Volume On NASDAQ Tuesday

    9/30/09 - Joint Venture / Alliance - View Story

  • BUYINS.NET: FITB, NVDA, YHOO, NWSA, DSCO, EBAY With Highest Daily Short Volume On NASDAQ Friday

    9/14/09 - Joint Venture / Alliance - View Story

  • Discovery Labs CEO resigns; chairman takes over

    8/13/09 - Mgmt. Change Leaving - CEO - View Story

  • Company and People Notes: Forest Labs and AstraZeneca Form Pact; Endo COO Resigns; More...

    8/19/09 - Mgmt. Change Leaving - Director - View Story

  • UPDATE 1-Discovery Labs posts narrower Q2 loss

    7/29/09 - Financial Announcement - View Story

News & Analysis

discovery laboratories inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
W. Thomas Amick Interim Chief Executive Officer
Antonio Esteve President, Laboratorios Del Dr. Esteve, S.A.
David L. Lopez Executive Vice President, General Counsel, Chief Compliance Officer and Secretary
John G. Cooper Executive. Vice President, Cfo
John I. Cooper CFO & Executive Vice President
Robert Segal Senior Vice President, Medical & Scientific Affairs, Chief Medical Officer
Charles F. Katzer Senior Vice President, Manufacturing Operations
Gerald J. Orehostky Senior Vice President, Quality Operations
Kathryn Cole Senior Vice President, Human Resources
Mary B. Templeton Deputy General Counsel & Senior Vice President
Thomas F. Miller Senior Vice President, Commercialization & Corporate Development
Vincent Benn Vice President, Clinical Operations, Worldwide
Charles G Cochrane Founder and Professor of Immunology, the Scripps R
Kathleen A. McGowan Director, Finance & Controller
Lisa Caperelli Manager, Investor Relations

Board of Directors

Name (plus bio) Position
Max Link Chairman
Tom Amick Chairman
Fernando R Moya Board of Directors
Herbert H. McDade Board of Directors
Marvin Rosenthale Board of Directors
T Allen Merritt Board of Directors

Organization Position Status
Aldagen, Inc. Chairman & CEO Current
Discovery Laboratories, Inc. Interim Chief Executive Officer Current
A. M. Pappas & Associates Venture Partner Current
Biolex, Inc. Observer Current
Discovery Laboratories, Inc. Chairman Current
Argolyn Bioscience, Inc. Chairman of the Board Current
Biolex, Inc. Board of Directors Current
Biorexis Pharmaceutical Corporation Board of Directors Current
Stemco Biomedical Chairman & CEO Former
Janssen-Ortho President Former
Ortho Biotech Inc. President Former
Johnson & Johnson Development Corp. Vice President of Business Development Former
Ortho Biotech Inc. Vice President of the Oncology Franchise Former
Johnson & Johnson oversaw J&J's pharmaceutical and biotechnology portfolios for Canada and Europe Former
Discovery Laboratories, Inc. Director Former
Elon University B.S. In Business Administration Former
Elon College B.S. Degree In Business Administration Former
Darden Graduate School of Business Administration NA Former
Harvard Business School Executive Courses Former
Kellogg School of Management at Northwestern University NA Former
Quaker Bioventures Member Former

Organization Position Status
Discovery Laboratories, Inc. President, Laboratorios Del Dr. Esteve, S.A. Current
Discovery Laboratories, Inc. Director Current
University of Barcelona Ph.D. In Pharmaceutical Science Former
University of Barcelona Degree In Pharmacy Former

David L. Lopez, C.P.A., Esq. - Executive Vice President and General Counsel, is responsible for all legal affairs of the company. Mr. Lopez also serves as the Company's Chief Compliance Officer overseeing its compliance committee. He has extensive experience in corporate and securities law, corporate finance, and tax and accounting matters. Previously to Discovery Labs, Mr. Lopez served as Senior Corporate Attorney at the Manhattan law firm of Roberts, Sheridan & Kotel. Prior to that, Mr. Lopez served as a Legal Research Specialist with the Securities and Exchange Commission. He has held increasingly senior corporate finance, tax and accounting related positions with Drexel Burnham Lambert, Price Waterhouse and Deloitte, Haskins & Sells. Mr. Lopez holds a B.S. in Economics and Accounting from Fairleigh Dickinson University and a J.D. from St. John's University School of Law.

Organization Position Status
Discovery Laboratories, Inc. Executive Vice President, General Counsel, Chief Compliance Officer and Secretary Current
St. John's University J.D. Former
Fairleigh Dickinson University B.S. In Economics and Accounting Former

John G. Cooper has been with the Company since December 2001 and currently serves as Executive Vice President, Chief Financial Officer and Treasurer. Mr. Cooper has over 25 years of extensive experience in managing emerging growth companies, including public and private equity financings, investor relations, strategic alliances, mergers and acquisitions, strategic and financial planning, and development of financial management and accounting systems. Prior to joining the Company, he served as Chief Financial Officer at Traffic.com, Inc., Chief Financial Officer at Taratec Development Corporation, a venture capital backed provider of information technology solutions to the life sciences industry, Senior Vice President and Chief Financial Officer of Chrysalis International Corporation (a public company acquired by MDS Pharmaceuticals, Inc.), Senior Vice President and Chief Financial Officer of DNX Corporation, a public biotechnology company, where Mr. Cooper managed its initial public offering in 1991, and Director, Finance and Controller of ENI Diagnostics (a public life sciences company acquired by Pharmacia). Mr. Cooper is a Certified Public Accountant and received his B.S. in Commerce from Rider University.

Organization Position Status
Discovery Laboratories, Inc. Executive. Vice President, Cfo Current
Mobility Technologies Chief Financial Officer Former
DNX Corporation Senior Vice President and Chief Financial Officer Former
Taratec Development Corp Chief Financial Officer Former
Chrysalis International Incorporated Chief Financial Officer Former
Chrysalis International Incorporated Senior Vice President Former
Rider University B.S. In Commerce Former

Organization Position Status
Discovery Laboratories, Inc. CFO & Executive Vice President Current
Discovery Laboratories, Inc. Executive Vice President, CFO Current
Chrysalis International Incorporated Chief Financial Officer Former
Mobility Technologies Chief Financial Officer Former
Taratec Development Corp Chief Financial Officer Former
Rider University B.S. in Commerce Former

Organization Position Status
Discovery Laboratories, Inc. Senior Vice President, Medical & Scientific Affairs, Chief Medical Officer Current
American College of Physicians Fellow Current
David Geffen School of Medicine at UCLA Assistant Professor of Medicine Former
Merck & Co. Inc. Director Former

Organization Position Status
Discovery Laboratories, Inc. Senior Vice President, Manufacturing Operations Current
MedImmune, Inc. Vice President, Vaccine Manufacturing Current
Rhone-Poulenc Rorer Pharmaceuticals, Inc. Former
University of Wisconsin B.S. Degree Former

Organization Position Status
Discovery Laboratories, Inc. Senior Vice President, Quality Operations Current
Palatin Technologies Inc. Executive Director of Quality Assurance and Regulatory Affairs Former
Schering-Plough Corporation Director Former
Thomas Edison State College B.A. Degree In Natural Science and Mathematics Former

Organization Position Status
Discovery Laboratories, Inc. Senior Vice President, Human Resources Current
Savient Pharmaceuticals, Inc. Vice President, Human Resources Former
Epigenesis Pharmaceuticals, LLC Former
Cytogen Corporation Former
Douglass College Undergraduate Degree In Communication Former
Rutgers University Former

Organization Position Status
Discovery Laboratories, Inc. Deputy General Counsel & Senior Vice President Current
Rutgers School of Law Board of Directors Current
The Sequor Group Senior Vice President and General Counsel Former
The Charles Schwab Corporation Director of Investment Company Products Former
Rutgers School of Law J.D. With High Honors Former
Chatham College B.A. Former

Organization Position Status
Discovery Laboratories, Inc. Senior Vice President, Commercialization & Corporate Development Current
Newbold Real Estate Co., Inc Sales Associate Current
Discovery Current
Johnson & Johnson Former
Pfizer Inc. Former
Pharmacia Corporation Former
Centocor, Inc. Director Former
Temple University Ph.D. degree in Cardio, respiratory Physiology Former
Temple University School of Medicine Ph.D Former
Fairleigh Dickinson University Mba Degree Former
Fairfield University B.S. Degree In Biology Former

Organization Position Status
Discovery Laboratories, Inc. Vice President, Clinical Operations, Worldwide Current

Organization Position Status
Discovery Laboratories, Inc. Founder and Professor of Immunology, the Scripps R Current
Discovery Laboratories, Inc. Board of Directors Current

Kathleen A. McGowan has been with the Company since June 2004 and serves as Director of Finance and Controller. Prior to joining the Company, from 2000, Ms. McGowan served as Director of Financial Analysis at Claneil Enterprises, Inc., a private equity investment firm. Previously, Ms. McGowan served as Financial Controller at The Liposome Company, Inc., a publicly-held biotech company acquired by Elan Corporation, plc., and as Controller at Nelson Communications, which was acquired by Publicis Healthcare Group, a leading U.S. healthcare communications company. From 1983 to 1995, Ms. McGowan also held financial management positions with Johnson & Johnson, primarily at Ortho-McNeil Pharmaceutical and Johnson & Johnson Corporate. Ms. McGowan received her B.S. in Finance and Accounting from Drexel University and an M.B.A. in Finance from Fairleigh Dickinson University.

Organization Position Status
Discovery Laboratories, Inc. Director, Finance & Controller Current
Claneil Enterprises, Inc. Director of Financial Analysis Former
The Liposome Company, Inc. Financial Controller Former
Fairleigh Dickinson University M.B.A. In Finance Former
Drexel University B.S. In Finance and Accounting Former

Organization Position Status
Discovery Laboratories, Inc. Manager, Investor Relations Current

Tom Amick, has 30 years experience with J&J where he spent most of his career in Ortho Biotech as a senior executive. Most recently he served as VP of Business development for Johnson & Johnson's Development Corporation (JJDC). Tom is an active Board member of emerging life science companies such as Biolex, Stemco (Chairman) among others.

Organization Position Status
Affinergy, Inc. Senior Executive Current
Discovery Laboratories, Inc. Chairman Current
Stemco Inc Active Board Member Current
Quaker Bioventures Advisory Board Member Current
Affinergy, Inc. Board of Directors Current
Biolex, Inc. Director Current
Transport Pharmaceuticals, Inc Board of Directors Current
Janssen-Ortho President Former
Johnson & Johnson Vice President of Business Development Former
Development Corp. Vice President of Business Development Former
Ortho Pharmaceutical Corporation Sales Representative Former

Organization Position Status
Discovery Laboratories, Inc. Board of Directors Current

Organization Position Status
Lehman Brothers Holdings Inc. President & Chief Operating Officer Current
Access Pharmaceuticals, Inc. Board of Directors Current
Discovery Laboratories, Inc. Board of Directors Current
Lehman Brothers Holdings Inc. Global Head, Equities Former
Lehman Brothers Holdings Inc. Global Head, Fixed Income Division Former
University of Michigan M.B.A. Former
Duke University B.A. Former

Organization Position Status
Discovery Laboratories, Inc. Board of Directors Current
Orphagen Director Current
Johnson & Johnson Vice President Former
McNeese State University Ph.D. In Pharmacology Former
Hospital Corp Ph.D. In Pharmacology Former
University of the Sciences in Philadelphia B.Sc. In Pharmacy Former

Organization Position Status
Discovery Laboratories, Inc. Board of Directors Current

Executive News

  • Company and People Notes: Forest Labs and AstraZeneca Form Pact; Endo COO Resigns; More...

    Pharmaceutical Technology - 8/19/09 - View Story

  • Discovery Labs CEO resigns

    Philadelphia Business Journal - 8/14/09 - View Story

  • Discovery Labs Announces Resignation of CEO Robert J. Capetola, Ph.D.; W. Thomas Amick, Chairman of the Board, Appointe

    NewsBlaze - 8/14/09 - View Story

  • Discovery Labs CEO resigns; chairman takes over

    CNBC - 8/13/09 - View Story

  • Discovery Labs Announces Resignation of CEO Robert J. Capetola, Ph.D.; W. Thomas Amick, Chairman of the Board, Appointed Interim CEO

    TradingMarkets - 8/13/09 - View Story

advertisement
Click Here
     DSCO $0.74 -0.02 (-2.60% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 7,531,830
Shares Outstanding 126.27M
Market Cap 93.8M
Year High 2.4
Year Low 0.3251
Earnings Per Share -0.31
P/E Ratio -2.40
Dividend N/A
Yield N/A
IndustryTop Rated
advertisement